ICB targets immune checkpoints, such as the CTLA-4 or the PD-1/PD-L1 axis with specific antibodies, and has achieved significant results in several cancer entities, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma of the head and neck (HNSCC) [7,8,9]. Here, CTLA4 is linked to non-small cell lung carcinoma.